Efficacy and safety of add-on dextromethorphan on irritability in children with ADHD treated with methylphenidate: A
1Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Objective:
Converging evidence suggests that childhood irritability is prospectively associated with major depressive disorder. Dextromethorphan has shown efficacious in improving depressive symptomatology in adults. This trial aimed to investigate the efficacy and safety of add-on dextromethorphan on irritability in children with attention-deficit/hyperactivity disorder (ADHD) receiving methylphenidate treatment.
Methods:
This randomized, double-blind, parallel-group trial evaluated dextromethorphan/methylphenidate versus placebo/methylphenidate in patients 7-17 years old with ADHD and comorbid irritability, which defined by the score of the Affective Reactivity Index (ARI) parent-report form ≥6. Patients were randomly assigned to receive optimal dose of methylphenidate and either dextromethorphan or placebo, 30 mg once daily for the first 2 weeks and 60 mg once daily thereafter, for a total of 8 weeks. The primary outcome was the change from baseline to week 8 in the ARI score.
Results:
A total of 19 patients were randomized (dextromethorphan, N = 8; placebo, N = 11), and Dextromethorphan was significantly superior to the placebo in reducing the ARI score at Week 2 (-5.82 points vs. -0.32 points; least-squares mean difference - 5.50; 95 % CI -8.13, -2.87), Week 4 (-6.49 points vs. -1.96 points; least-squares mean difference - 4.53; 95 % CI -7.13, -1.94), and Week 8 (-4.98 points vs. -2.21 points; least-squares mean difference - 2.77; 95 % CI -5.29, -0.24). The effects of treatment by time interaction were significant at week 2, week 4, and week 8 (p < 0.001, p < 0.001, and p = 0.015, respectively).
Conclusions:
Adjunctive dextromethorphan might be efficacious in the treatment of irritability in children with ADHD treated with methylphenidate.
More Related Videos
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
01:28Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:30Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
01:23Antidepressant Drugs: MAOIs and Other Agents
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...